🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,328 results for “Xiyuan Hospital of China Academy of Chinese Medical Sciences” Clear

  1. Zanubrutinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  2. Zanubrutinib, Fludarabine, cyclophosphamide and rituximab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Chronic Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  3. Zaunbrutinib, Bendamustine and Rituximab for induction therapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Waldenström Macroglobulinemia (WM)

    phase 2 small molecule active

    1 trial

  4. Zuberitamab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    HSCT

    phase 2 small molecule active

    1 trial

  5. anlotinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Sarcoma, Soft Tissue

    phase 2 small molecule active

    1 trial

  6. anti-BCMA CAR-T

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Plasma Cell Leukemia

    phase 2 mab active

    1 trial

  7. anti-BCMA-CAR-T

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Multiple Myeloma

    phase 2 mab active

    2 trials

  8. anti-BCMA/CD3 bispecific antibody

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  9. befotertinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    NSCLC (Non-small Cell Lung Cancer)

    phase 2 small molecule active

    1 trial

  10. benmelstobart

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    SCLC, Extensive Stage

    phase 2 small molecule active

    1 trial

  11. bortezomib/dexamethasone

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acquired Pure Red Cell Aplasia

    phase 2 small molecule completed

    1 trial

  12. cadonilimab combined +paclitaxel (albumin-bound)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gastric Adenocarcinoma

    phase 2 small molecule active

    1 trial

  13. cell sheet pellets and cell sheet fragment

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Chronic Periodontitis

    phase 2 mab active

    1 trial

  14. cetuximab (Erbitux)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Esophageal Cancer

    phase 2 small molecule completed

    1 trial

  15. chemotherapy: TS-1, Leucovorin and Gemcitabine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pancreatic Adenocarcinoma

    phase 2 small molecule completed

    1 trial

  16. cisplatin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  17. citalopram

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Major Depressive Disorder

    phase 2 small molecule completed

    1 trial

  18. convention therapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Stroke

    phase 2 small molecule completed

    1 trial

  19. conventional therapy plus low dose hUC-MSCs treatment

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Liver Cirrhosis

    phase 2 mab completed

    1 trial

  20. corticosteroids

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Severe Colitis (ASC)

    phase 2 small molecule active

    1 trial

  21. corticosteroids combined with immunoglobulin and romiplostim

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Primary Immune Thrombocytopenia

    phase 2 small molecule active

    1 trial

  22. dapagliflozin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Kidney Injury

    phase 2 small molecule active

    1 trial

  23. deferoxamine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Intracerebral Hemorrhage

    phase 2 small molecule active

    1 trial

  24. docetaxel, cisplatin, fluorouracil

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Locally Advanced Head and Neck Carcinoma

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources